Clinical Trial Update: Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF) [Phase 4]

View source ↗

Summary

Phase 4 trial update on dapagliflozin in acute heart failure with reduced ejection fraction assessing clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Cairo University | Conditions: Acute Heart Failure | Phase 4 | Status: COMPLETED